Cost-effectiveness of a “treat-all” strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages

AIM: To evaluate the cost-effectiveness of therapeutic strategies initiated at different stages of liver fibrosis using three direct-acting antivirals (DAAs), sofosbuvir-ledipasvir (SL), glecaprevir-pibrentasvir (GP), and elbasvir plus grazoprevir (E/G), for Japanese patients with chronic hepatitis...

Descripción completa

Detalles Bibliográficos
Autores principales: Suenaga, Riichiro, Suka, Machi, Hirao, Tomohiro, Hidaka, Isao, Sakaida, Isao, Ishida, Haku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016275/
https://www.ncbi.nlm.nih.gov/pubmed/33793594
http://dx.doi.org/10.1371/journal.pone.0248748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016275/
https://www.ncbi.nlm.nih.gov/pubmed/33793594
http://dx.doi.org/10.1371/journal.pone.0248748

Ejemplares similares